To evaluate the role of ROC1 in bladder cancer proliferation, we first assessed the oncogenic activity of ROC1 in bladder cancer 5637 and T24 cells by stable transfection of ROC1 cDNA (p-ROC1) or small interfering RNA (siRNA) (siROC1), while the empty vector (p-CONT) and the negative control siRNA (siCONT) were used as controls, respectively (Additional file 1: Fig. S1). Here, RBX1 is linked to urinary bladder carcinoma.